June 2026 · 7 min read
GHK-Cu and wound repair: the literature the copper-peptide field was built on
A summary of published research, with citations. It states no amount, schedule or route, and makes no claim about what this compound does in a person. Supplied for laboratory research use only.
Every other GHK-Cu research thread — skin ageing, hair, inflammation — is downstream of the repair work. That is not a rhetorical point about priority. It is why the compound is discussed in terms of collagen, fibroblasts and matrix biology at all, and why those terms get reused in contexts where they were never tested.
This article is about the repair thread itself: where the compound came from, what the foundational experiments actually measured, and what they did not. For the UV-damage thread, which shares the mechanisms but not the endpoints, see GHK-Cu and photoageing. Nothing here is medical, dosing, or therapeutic guidance.
Where the molecule came from
In the 1970s Loren Pickart was working with human plasma fractions and reported that fractions from young donors had tissue-repair activity that fractions from older donors lacked. Isolating the responsible component led to a tripeptide — glycine-histidine-lysine, a fragment of larger proteins released when tissue is injured. The second finding was the one that made a field: the tripeptide binds copper preferentially, and the copper complex was reported to behave differently from the metal-free peptide.
Three things follow from that origin, and they are worth holding separately because they get merged.
The peptide is a fragment of injured tissue rather than a designed molecule. The copper is part of the entity under study, not a counterion. And the early work was descriptive cell biology — it catalogued effects on cellular processes, which is a different kind of claim from showing a wound closes faster.
The founding experiment was in a dish
The result the whole field rests on is Maquart and colleagues in 1988: collagen synthesis stimulated in fibroblast cultures by the GHK-copper complex. It is a clean, specific, much-cited finding, and it is fibroblast culture. Not a wound. Not an animal. Cells in a plate, producing more of a protein.
Most of what has been written since either extends that result into other cell types or reasons forward from it into tissue-level outcomes. The reasoning forward is where the literature gets thin, and the reader has to do the work of noticing when it happens.
Repair has four phases, and the data are not spread evenly across them
| Phase | What happens | Timescale |
|---|---|---|
| Haemostasis | Platelet aggregation, clot formation | Minutes to hours |
| Inflammation | Neutrophil and macrophage recruitment, debris clearance | Hours to days |
| Proliferation | Fibroblast proliferation, collagen deposition, angiogenesis, epithelial migration | Days to weeks |
| Remodelling | Collagen reorganisation, scar maturation, return toward normal mechanics | Weeks to months |
The phases matter because a compound can accelerate one and worsen the result. Suppressing inflammation too early leaves debris behind; accelerating deposition without organising it produces a bulkier, weaker scar. Any honest account of a repair compound has to say which phase it was measured in.
For GHK-Cu, the answer is overwhelmingly proliferation. Collagen type I and III synthesis, fibroblast proliferation and migration, glycosaminoglycan production and angiogenesis are the endpoints the published work concentrates on, which is unsurprising given where the compound was found and which assays were available.
Inflammation is a thinner and more interesting case. The reported effects on TNF-α, IL-6 and NF-κB activity are described as modulation rather than suppression (PMID 29986520), which, in a repair context, is the difference between helping a phase resolve and preventing it. Whether the published data distinguish those two outcomes well is a fair question to put to any given paper.
Remodelling has the least. MMP and TIMP expression have been examined, and some work asks whether scar mechanics differ, but this is where the measurements get difficult and the literature correspondingly sparse.
Copper, and the gap in the copper argument
Three copper-dependent enzymes come up whenever this compound is explained:
- Lysyl oxidase, which crosslinks collagen fibrils and so determines how strong healed tissue actually is
- Cu/Zn superoxide dismutase, which handles the oxidative stress a wound bed generates
- Cytochrome c oxidase, which the mitochondrial energy production of a proliferating phase depends on
All three are real, and all three are facts about copper rather than findings about GHK-Cu. The step that is usually asserted and rarely demonstrated is that this tripeptide delivers copper to those enzymes in healing tissue in a way that changes their output. The copper chemistry gives the compound a plausible mechanism; plausible mechanisms are cheap, and this one has not been closed.
Where the evidence stops
Culture and animals. The mechanistic literature is cell culture with supporting animal work. It is not a human trial programme.
No approval anywhere. GHK-Cu is not approved as a wound-healing drug by Health Canada, the FDA or the EMA. It appears in cosmetic ingredient listings as copper tripeptide-1 — a safety and labelling regime, which permits a substance in a product and says nothing about whether it works.
Chronic wounds are a different problem. Diabetic and pressure ulcers fail to heal because of perfusion, infection and persistent inflammation, not because a tripeptide is missing. Mechanistic logic from acute repair does not extend to them by default, and the published GHK-Cu work does not establish that it does.
The reviews come from the people who found it. Pickart's group authored the compound's principal modern syntheses (PMID 29986520, PMID 26236730). That is normal for a molecule one laboratory discovered, and it means the field's framing and its evidence come from the same source. Independent replication is the thing to look for.
Reported in culture is not reported in tissue. More collagen in a plate is not a stronger scar. Mechanical testing of healed tissue is the demanding endpoint, and it is the one this literature has least of.
What that leaves for a research question
The repair thread is where the compound has its most direct evidence, because proliferation-phase endpoints are what it was characterised against. Questions about fibroblast behaviour, matrix deposition and angiogenesis in a controlled model sit closest to the published groundwork. Questions about healed-tissue mechanics, chronic wounds or anything in a person sit a long way from it.
Reconstitution is arithmetic and nothing more: a 50 mg vial taken up in 5 mL of diluent gives 10 mg/mL, and the 100 mg vial in the same volume gives 20 mg/mL.
GHK-Cu is supplied here as GHK-Cu, in 50 mg and 100 mg vials. Janoshik-verified by HPLC with mass-spec identity confirmation; 100% synthetic. The measured purity for each lot is stated on its product page. For laboratory research use only.
Common questions
Why is wound repair called the foundational application? Because the compound was found by looking for tissue-repair activity in plasma fractions, and the first biological result was collagen synthesis in fibroblast culture. The skin, hair and inflammation threads reuse the mechanisms that work established.
Which repair phase has the most data? Proliferation, by a wide margin — collagen synthesis, fibroblast proliferation and migration, glycosaminoglycan production, angiogenesis. Inflammation is reported as modulation rather than suppression. Remodelling has the least, which matters because remodelling determines mechanical strength.
Does the copper do the work? The copper complex is reported to differ from the free tripeptide, and several repair-relevant enzymes are copper-dependent. Those two statements are often presented as one argument. They are not: no published work ties this peptide's activity to the output of lysyl oxidase or superoxide dismutase in healing tissue.
Has it been shown to heal a human wound? No. There is no controlled human trial establishing that, and no regulator has approved it for wound care in Canada, the United States or the EU.
Selected Research References
- Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide. International Journal of Molecular Sciences. 2018;19(7):1987. pubmed.ncbi.nlm.nih.gov/29986520
- Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International. 2015;2015:648108. pubmed.ncbi.nlm.nih.gov/26236730
- Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. Stimulation of Collagen Synthesis in Fibroblast Cultures by the Tripeptide-Copper Complex Glycyl-L-Histidyl-L-Lysine-Cu2+. FEBS Letters. 1988;238(2):343-346. (Foundational copper-peptide collagen research from Pickart's era.)
- Sciumè G, Le Bideau J, Gokel GW, et al. Copper Tripeptide GHK-Cu and Tissue Repair: A Review. Journal of Biological Inorganic Chemistry. (Reference on copper-peptide wound healing research consolidation.)
All products sold by NovaEvum are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.